HCW Biologics Inc. — Q3 2022 Form 10-Q
Business context and reporting period. This clinical-stage biopharmaceutical company develops immunotherapies targeting chronic inflammation and age-related diseases. The unaudited quarter and nine-month periods ended September 30, 2022 are compared with the corresponding 2021 periods. HCW9218 is in Phase 1 cancer studies; HCW9302 remains in IND-enabling development. The company has no approved products or commercial product sales.
Financial performance and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue (2022; 2021) | $1.81 million; none | $5.38 million; none |
| Cost of revenue (2022) | $1.45 million | $3.06 million |
| Net revenue / gross profit (2022) | $0.36 million; approximately 20% of revenue | $2.32 million; approximately 43% of revenue |
| Research and development expense (2022; 2021) | $2.65 million; $2.69 million | $6.41 million; $6.69 million |
| General and administrative expense (2022; 2021) | $1.73 million; $1.40 million | $5.32 million; $3.57 million |
| Net loss (2022; 2021) | $3.91 million; $4.09 million | $9.48 million; $9.69 million |
| Basic and diluted loss per share (2022; 2021) | $0.11; $0.14 | $0.26; $0.74 |
Revenue arose from supplying clinical and research-grade materials to Wugen under statements of work, not from product sales. Q3 operating loss was $4.02 million versus $4.09 million a year earlier; nine-month operating loss was $9.41 million versus $10.26 million. The nine-month net loss improvement includes lower operating loss, partly offset by a swing in interest and other income/loss.
- Cash flow: Operating cash used was $6.60 million for the first nine months of 2022, compared with $7.60 million in 2021. Investing activities provided $14.78 million, primarily from $24.98 million of maturing short-term investments, offset by $10.21 million of property and equipment purchases. Financing provided $6.31 million, principally from the headquarters loan. Cash increased $14.49 million to $26.22 million.
- Liquidity: At September 30, 2022, cash and cash equivalents were $26.22 million; U.S. Treasury notes were $9.67 million. Total current assets were $28.71 million and current liabilities $2.29 million. The company also held a $1.6 million minority investment in Wugen, which is not publicly traded and has limited liquidity.
- Debt and assets: The company reported $6.45 million of debt net of issuance costs (gross principal $6.5 million). Property and equipment, net, rose to $10.96 million from $1.12 million after the headquarters purchase. Total assets were $51.35 million and stockholders’ equity $42.56 million.
Material changes versus the prior comparable period
- Wugen supply revenue began being recognized after the company executed statements of work in March 2022. The prior-year periods reported no revenue.
- Nine-month G&A expense rose 49%, mainly due to post-IPO CEO stock-based compensation, higher public-company insurance costs, and other public-company expenses. Q3 G&A rose 23% year over year.
- Nine-month R&D expense declined 4%, chiefly because manufacturing and materials costs were lower; clinical-trial spending increased 114% from a smaller base.
- The company bought a Miramar headquarters building for approximately $10.1 million, funded partly by a five-year, $6.5 million secured loan and partly with cash. It also entered a one-year leaseback arrangement with the former owner.
- Short-term Treasury bills held at year-end 2021 matured during 2022; the company reported Treasury notes as long-term investments at September 30.
Outlook, commentary, risks and unusual items
- Management estimated available capital would fund operations and facility buildout through the end of 2023, but cautioned that estimates depend on assumptions and that additional capital may be needed. The company may seek equity or collaboration funding; its effective shelf registration includes an ATM program for up to $15.5 million, which is potential financing capacity, not cash already raised.
- Management expects R&D spending and clinical costs to increase as trials advance. It targeted preliminary pancreatic-cancer trial data in the first half of 2023. HCW9302 IND-enabling toxicology work was delayed, with completion and a planned IND filing expected in the first half of 2023, subject to further delays.
- The company reported no dose-limiting toxicity in the Masonic Cancer Center HCW9218 Phase 1 study as of September 30; patients had been treated at two dose levels. The first patient in the company-sponsored pancreatic cancer trial was dosed in October 2022, after quarter-end. These are early-stage observations, not evidence of efficacy or definitive safety.
- COVID-related staffing and supply-chain issues had delayed clinical-site activity and IND-enabling studies. Inflation, higher interest rates, geopolitical tensions, and supply disruption may increase costs or delay development and headquarters construction.
- Allegations by the CEO’s former employer concerning core intellectual property were disclosed. The filing said no claims had been filed, but the company incurred legal expenses and agreed to advance defense costs under its indemnification arrangements. The potential financial exposure is unclear.
- Future payments under contract manufacturing agreements were approximately $2.0 million at quarter-end. The company also disclosed indemnification obligations whose maximum potential payments are not determinable.
- The company reported a full valuation allowance on deferred tax assets and no income tax provision. Management concluded disclosure controls were effective as of September 30, 2022, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether Wugen supply arrangements continue to generate revenue, and the timing and terms of any future Wugen milestones, royalties, or supply work.
- Actual cash burn, clinical and manufacturing commitments, headquarters buildout costs, and whether funding will be sufficient beyond the company’s stated end-of-2023 estimate.
- Progress, enrollment, safety findings, and eventual efficacy evidence from HCW9218 trials; verify the timing of the pancreatic study readout and HCW9302 IND submission.
- Developments in the former-employer intellectual-property matter, including any formal claims, defense costs, indemnification exposure, or effect on the company’s IP rights.
- Use and terms of any ATM or other financing, including potential dilution; confirm no ATM proceeds are reported here.